Language
English
Publication Date
1-17-2025
Journal
Nature Communications
DOI
10.1038/s41467-025-55931-w
PMID
39824819
PMCID
PMC11748719
PubMedCentral® Posted Date
1-17-2025
PubMedCentral® Full Text Version
Post-print
Abstract
Neutralizing antibody titer has been a surrogate endpoint for guiding COVID-19 vaccine approval and use, although the pandemic's evolution and the introduction of variant-adapted vaccine boosters raise questions as to this surrogate's contemporary performance. For 985 recipients of an mRNA second bivalent or monovalent booster containing various Spike inserts [Prototype (Ancestral), Beta, Delta, and/or Omicron BA.1 or BA.4/5] in the COVAIL trial (NCT05289037), titers against 5 strains were assessed as correlates of risk of symptomatic COVID-19 ("COVID-19") and as correlates of relative (Pfizer-BioNTech Omicron vs. Prototype) booster protection against COVID-19 over 6 months of follow-up during the BA.2-BA.5 Omicron-dominant period. Consistently across the Moderna and Pfizer-BioNTech vaccine platforms and across all variant Spike inserts assessed, both peak and exposure-proximal ("predicted-at-exposure") titers correlated with lower Omicron COVID-19 risk in individuals previously infected with SARS-CoV-2, albeit significantly less so in naïve individuals [e.g., exposure-proximal hazard ratio per 10-fold increase in BA.1 titer 0.74 (95% CI 0.59, 0.94) for naïve vs. 0.41 (95% CI 0.23, 0.64) for non-naïve; interaction p = 0.013]. Neutralizing antibody titer was a strong inverse correlate of Omicron COVID-19 in non-naïve individuals and a weaker correlate in naïve individuals, posing questions about how prior infection alters the neutralization correlate.
Keywords
Humans, Antibodies, Neutralizing, COVID-19, COVID-19 Vaccines, SARS-CoV-2, Antibodies, Viral, Female, Male, Immunization, Secondary, Middle Aged, Adult, Spike Glycoprotein, Coronavirus, mRNA Vaccines, Vaccines, Synthetic, RNA vaccines, Statistics, Medical research, Infectious diseases, Antibodies
Published Open-Access
yes
Recommended Citation
Zhang, Bo; Fong, Youyi; Dang, Lauren; et al., "Neutralizing Antibody Immune Correlates in Covail Trial Recipients of an Mrna Second COVID-19 Vaccine Boost" (2025). Faculty and Staff Publications. 5663.
https://digitalcommons.library.tmc.edu/baylor_docs/5663
Included in
Allergy and Immunology Commons, Biological Phenomena, Cell Phenomena, and Immunity Commons, Clinical Epidemiology Commons, COVID-19 Commons, Pathology Commons